This patent concerns the method of preventing disintegration and aggregation of stem cells. It is also regards the stem cell composite product that is characterized by suspension of stem cells in an aspirin solution and is intravenously administered. In addition, it concerns a composite product for the prevention of disintegration and aggregation of stem cells, which characteristically become suspended in an aspirin solution.
This patented method can prevent disintegration and aggregation of cells during transport and storage, and effectively, allowing the administered stem cells to reach the target tissue area and effectively enhance the effectiveness of activation. Accordingly, it can substantially promote the efficacy of cell therapy in which stem cells are used.Leave a reply